Comparison of antithrombotic efficacy and haemorrhagic side-effects of Clivarin versus enoxaparin in patients undergoing total hip replacement surgery.
A study of equivalence was performed between two low molecular weight heparins, reviparin-sodium (Clivarin) and enoxaparin (Lovenox) in the prevention of deep vein thrombosis (DVT) after total hip replacement. Nineteen orthopaedic centres participated in the trial. Four hundred and ninety-eight patients were randomized; 247 received reviparin-sodium and 251 enoxaparin; 58 patients were excluded. Each patient received subcutaneous prophylaxis begun 10-12 h pre-operatively and the second injection 10-12 h post-operatively and thereafter every 24 h. In the enoxaparin group 18 DVT were observed (9%); of these 13 (6%) were proximal. In the reviparin-sodium group 21 DVT were observed (10%); 12 (6%) were proximal. The study showed that the efficacy of both LMWHs was equivalent as was the clinical tolerance. There was a slight trend in favour of reviparin-sodium as regards haemoglobin level, and wound haematoma. Anti-factor Xa activity was significantly different despite similar injected doses.
Planes
A
A
Clinique Radio Chirurgicale, La Rochelle, France.
D000368:Aged; D017984:Enoxaparin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D065427:Factor Xa Inhibitors; D006470:Hemorrhage / Q000139:chemically induced* / Q000453:epidemiology; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006622:Hip Prosthesis; D006801:Humans; D007279:Injections, Subcutaneous; D008875:Middle Aged; D011183:Postoperative Complications / Q000453:epidemiology / Q000517:prevention & control*; D011446:Prospective Studies; D013923:Thromboembolism / Q000453:epidemiology / Q000517:prevention & control*; D016896:Treatment Outcome
D017984:Enoxaparin; D065427:Factor Xa Inhibitors; D006495:Heparin, Low-Molecular-Weight; C094240:reviparin